title: Understanding alternative splicing of Cav1.2 calcium channels for a new approach towards individualized medicine.
abstract: Calcium channel blockers (CCBs) are widely used to treat cardiovascular diseases such as hypertension, angina pectoris, hypertrophic cardiomyopathy, and supraventricular tachycardia. CCBs selectively inhibit the inward flow of calcium ions through voltage-gated calcium channels, particularly Cav1.2, that are expressed in the cardiovascular system. Changes to the molecular structure of Cav1.2 channels could affect sensitivity of the channels to blockade by CCBs. Recently, extensive alternative splicing was found in Cav1.2 channels that generated wide phenotypic variations. Cardiac and smooth muscles express slightly different, but functionally important Cav1.2 splice variants. Alternative splicing could also modulate the gating properties of the channels and giving rise to different responses to inhibition by CCBs. Importantly, alternative splicing of Cav1.2 channels may play an important role to influence the outcome of many cardiovascular disorders. Therefore, the understanding of how alternative splicing impacts Cav1.2 channels pharmacology in various diseases and different organs may provide the possibility for individualized therapy with minimal side effects.
authors.affiliation: National Neuroscience Institute, 11 Jalan Tan Tock Seng, Singapore 308433.
authors.forename: Ping
authors.initials: P
authors.lastname: Liao
authors.forename: Tuck Wah
authors.initials: TW
authors.lastname: Soong
references.citation: Nature. 1983 Apr 28;302(5911):790-4
references.pmid: 6302512
references.citation: J Mol Cell Cardiol. 2000 Jun;32(6):973-84
references.pmid: 10888251
references.citation: Circ Res. 1997 Oct;81(4):526-32
references.pmid: 9314833
references.citation: FEBS Lett. 1998 May 8;427(2):220-4
references.pmid: 9607315
references.citation: Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8089-96; discussion 8086-8
references.pmid: 15863612
references.citation: J Biol Chem. 1998 Jul 10;273(28):17901-9
references.pmid: 9651396
references.citation: J Biol Chem. 2004 Oct 22;279(43):44335-43
references.pmid: 15299022
references.citation: J Biol Chem. 2004 Nov 26;279(48):50329-35
references.pmid: 15381693
references.citation: Br J Pharmacol. 1998 Nov;125(5):1005-12
references.pmid: 9846638
references.citation: Cardiovasc Res. 2005 Jan 1;65(1):28-39
references.pmid: 15621031
references.citation: J Biol Chem. 2007 Nov 30;282(48):35133-42
references.pmid: 17916557
references.citation: Trends Cardiovasc Med. 2004 Jan;14(1):23-8
references.pmid: 14720471
references.citation: J Biol Chem. 1995 May 5;270(18):10540-3
references.pmid: 7737988
references.citation: Annu Rev Cell Dev Biol. 2000;16:521-55
references.pmid: 11031246
references.citation: Mol Pharmacol. 1998 May;53(5):902-7
references.pmid: 9584217
references.citation: N Engl J Med. 1999 Nov 4;341(19):1447-57
references.pmid: 10547409
references.citation: Cell. 1996 Nov 1;87(3):543-52
references.pmid: 8898206
references.citation: Cell Physiol Biochem. 1999;9(4-5):242-69
references.pmid: 10575201
references.citation: Cell Calcium. 2007 May;41(5):417-28
references.pmid: 16979758
references.citation: J Gen Physiol. 1991 Aug;98(2):265-85
references.pmid: 1658192
references.citation: J Lab Clin Med. 1999 May;133(5):469-77
references.pmid: 10235130
references.citation: Biochim Biophys Acta. 2008 Jan;1783(1):118-30
references.pmid: 18070605
references.citation: J Biol Chem. 2007 Oct 5;282(40):29211-21
references.pmid: 17699517
references.citation: J Pharmacol Exp Ther. 2002 Mar;300(3):724-8
references.pmid: 11861774
references.citation: J Biol Chem. 2000 Dec 15;275(50):39193-9
references.pmid: 10973973
references.citation: FEBS Lett. 1990 Sep 3;269(2):409-12
references.pmid: 2169433
references.citation: Can J Cardiol. 1995 Mar;11(3):243-9
references.pmid: 7889444
references.citation: J Physiol. 1997 Apr 15;500 ( Pt 2):311-7
references.pmid: 9147319
references.citation: Pflugers Arch. 2009 Jul;458(3):481-7
references.pmid: 19151996
references.citation: Cell. 2004 Oct 1;119(1):19-31
references.pmid: 15454078
references.citation: Pharmacogenomics. 2006 Apr;7(3):271-9
references.pmid: 16610939
references.citation: Circ Res. 2000 Dec 8;87(12):1095-102
references.pmid: 11110765
references.citation: Hypertension. 1983 Jul-Aug;5(4 Pt 2):II97-102
references.pmid: 6345378
references.citation: Pflugers Arch. 2009 Aug;458(4):701-11
references.pmid: 19263075
references.citation: J Cardiovasc Pharmacol. 1991;18 Suppl 10:S1-6
references.pmid: 1724996
references.citation: Annu Rev Pharmacol Toxicol. 1997;37:361-96
references.pmid: 9131258
references.citation: Cardiovasc Res. 2005 Nov 1;68(2):197-203
references.pmid: 16051206
references.citation: Nature. 1988 Nov 24;336(6197):382-5
references.pmid: 2848201
references.citation: Nature. 1994 Nov 3;372(6501):97-100
references.pmid: 7969428
references.citation: J Biol Chem. 2004 Dec 31;279(53):55211-7
references.pmid: 15504730
references.citation: Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):17024-9
references.pmid: 17071743
references.citation: Am J Physiol Cell Physiol. 2001 Dec;281(6):C1743-56
references.pmid: 11698232
references.citation: Trends Pharmacol Sci. 1998 Mar;19(3):108-15
references.pmid: 9584627
references.citation: Biochem Biophys Res Commun. 1995 Nov 22;216(3):892-7
references.pmid: 7488209
references.citation: Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):11914-8
references.pmid: 7527547
references.citation: Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1497-501
references.pmid: 1311102
references.citation: J Biol Chem. 2001 Jan 12;276(2):1398-406
references.pmid: 11010971
references.citation: Nature. 1989 Jul 20;340(6230):230-3
references.pmid: 2474130
references.citation: Pharmacogenet Genomics. 2006 Oct;16(10):735-45
references.pmid: 17001293